Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JIBRAN E ATWI

Allopathic & Osteopathic Physicians Allergy & Immunology

NPI
1154322923
CMS profile
142445
Location
LAFAYETTE, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$946.82

51 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $887.82 49
Education $59.00 2

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JIBRAN E ATWI

NPI 1154322923 · CMS profile ID 142445

Allopathic & Osteopathic Physicians / Allergy & Immunology

LAFAYETTE, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1154322923?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JIBRAN E ATWI, NPI 1154322923, CMS profile ID 142445. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1154322923?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). JIBRAN E ATWI, NPI 1154322923, CMS profile ID 142445. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1154322923?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
JIBRAN E ATWI, NPI 1154322923, CMS profile ID 142445, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1154322923?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

51 matching records · $946.82 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 51 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–51 of 51.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GENZYME CORPORATION $12.2001/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233640153 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $186.56 11
PY2020 $95.20 7
PY2021 $322.65 20
PY2022 $449.36 28
PY2023 $479.49 24
PY2024 $858.96 43
PY2025 $946.82 51

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,678,691.77 331
PY2024 Recipient $1,002.46 7
PY2024 Principal investigator $3,616,597.58 183
PY2023 Recipient $1,120.25 4
PY2023 Principal investigator $2,225,098.34 177
PY2022 Principal investigator $1,051,985.35 225
PY2021 Principal investigator $102,186.90 23

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

331 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $849.75 12/31/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Safety and Efficacy Study of Linaclotide versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, with Functional Constipation (FC) with a 24-week Open-label Treatment Extension No dispute reported 06/30/2026 1202535093
Principal investigator 1 ABBVIE INC. $695.25 12/31/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 2 Dose Finding Study Evaluating the Safety and Efficacy of Linaclotide in Pediatric Subjects 6 Months to Less Than 2 Years of Age with Functional Constipation (FC). No dispute reported 06/30/2026 1202535095
Principal investigator 1 Merck Sharp & Dohme LLC $43,881.48 12/31/2025 Non-covered Recipient Entity
Velocity Clinical Research, Lafayette
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Children and Adolescents With Increased Risk of Pneumococcal Disease No dispute reported 06/30/2026 1232934498
Principal investigator 1 Currax Pharmaceuticals LLC $4,608.54 12/24/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242718386
Principal investigator 1 ModernaTX, Inc. $10,000.00 12/23/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Post marketing commitment study to assess clinical efficacy & safety of current JN.1-based formulation with focus on lower-risk adults (50-64 years) to inform benefit-risk profile (PMC2) No dispute reported 06/30/2026 1252946550
Principal investigator 1 Seqirus USA Inc $47.60 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273766
Principal investigator 1 Seqirus USA Inc $406.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273768
Principal investigator 1 Seqirus USA Inc $819.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273770
Principal investigator 1 Seqirus USA Inc $1,019.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273772
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273774
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273778
Principal investigator 1 Seqirus USA Inc $406.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185279441
Principal investigator 1 Seqirus USA Inc $406.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185279443
Principal investigator 1 Seqirus USA Inc $406.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185279445
Principal investigator 1 Seqirus USA Inc $406.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185279447
Principal investigator 1 Seqirus USA Inc $406.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185279449
Principal investigator 1 Seqirus USA Inc $406.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185279451
Principal investigator 1 Seqirus USA Inc $406.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185279453
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280665
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280667
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280669
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280671
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280673
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280675
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280677
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280679
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280681
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280683
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280685
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280687
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280689
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280691
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280693
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280823
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280825
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280827
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280829
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280831
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280833
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280837
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280839
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280841
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280843
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280845
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280847
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280849
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280851
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280853
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280855
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280857
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280859
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280861
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280863
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280865
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280867
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280869
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280871
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280873
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280875
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280935
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280937
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280939
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280941
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280943
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280945
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280947
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280949
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280951
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280953
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280955
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280957
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280959
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280961
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280963
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280965
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280967
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280969
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280971
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280973
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280975
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280977
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280979
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280981
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280983
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280985
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280987
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280989
Principal investigator 1 ModernaTX, Inc. $626.00 12/17/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1252955419
Principal investigator 1 ModernaTX, Inc. $644.47 12/17/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252955437
Principal investigator 1 ModernaTX, Inc. $1,357.00 12/17/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1252955513
Principal investigator 1 ModernaTX, Inc. $1,500.00 12/17/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1252955555
Principal investigator 1 ModernaTX, Inc. $900.00 12/17/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1252955559
Principal investigator 1 ABBVIE INC. $7,750.00 12/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation No dispute reported 06/30/2026 1202530580
Principal investigator 1 ABBVIE INC. $354.00 12/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation No dispute reported 06/30/2026 1202530592
Principal investigator 1 SANOFI US SERVICES INC. $16,666.00 12/15/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226130802
Principal investigator 1 Novavax Inc $250,556.40 12/12/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, open-label, single arm study to evaluate the safety and immunogenicity of a single dose of an Omicron JN. No dispute reported 06/30/2026 1242919974
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $598.50 12/11/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046672
Principal investigator 1 SANOFI US SERVICES INC. $2,572.80 12/08/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226130786
Principal investigator 1 Novavax Inc $14,500.00 12/01/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, open-label, single arm study to evaluate the safety and immunogenicity of a single dose of an Omicron JN. No dispute reported 06/30/2026 1242918770
Principal investigator 1 Novavax Inc $1,700.00 12/01/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, open-label, single arm study to evaluate the safety and immunogenicity of a single dose of an Omicron JN. No dispute reported 06/30/2026 1242919489
Principal investigator 1 Novavax Inc $105,809.40 12/01/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, open-label, single arm study to evaluate the safety and immunogenicity of a single dose of an Omicron JN. No dispute reported 06/30/2026 1242920853
Principal investigator 1 ModernaTX, Inc. $3,724.00 11/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252955481
Principal investigator 1 ModernaTX, Inc. $3,769.60 11/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252955517
Principal investigator 1 ModernaTX, Inc. $425.00 11/26/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003491
Principal investigator 1 ModernaTX, Inc. $1,444.00 11/26/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003503
Principal investigator 1 ModernaTX, Inc. $30,000.00 11/25/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Post marketing commitment study to assess clinical efficacy & safety of current JN.1-based formulation with focus on lower-risk adults (50-64 years) to inform benefit-risk profile (PMC2) No dispute reported 06/30/2026 1252946548
Principal investigator 1 SANOFI PASTEUR INC. $1,000.00 11/25/2025 Non-covered Recipient Entity
Velocity Clinical Research,inc
A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers No dispute reported 06/30/2026 1226089867
Principal investigator 1 SANOFI PASTEUR INC. $625.00 11/25/2025 Non-covered Recipient Entity
Velocity Clinical Research,inc
A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers No dispute reported 06/30/2026 1226089884
Principal investigator 1 GlaxoSmithKline, LLC. $575.00 11/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192133321
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 11/20/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, DOSE FINDING STUDY TO No dispute reported 06/30/2026 1192130908
Principal investigator 1 SANOFI US SERVICES INC. $22,469.00 11/17/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226130745
Principal investigator 1 SANOFI PASTEUR INC. $2,010.82 11/14/2025 Non-covered Recipient Entity
Velocity Clinical Research,inc
A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers No dispute reported 06/30/2026 1226089980
Principal investigator 1 Currax Pharmaceuticals LLC $4,186.67 11/13/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242718228
Principal investigator 1 GlaxoSmithKline, LLC. $8,024.00 11/12/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A PHASE 3A, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 1192133341
Principal investigator 1 Novartis Pharmaceuticals Corporation $300.28 11/10/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH LAFAYETTE
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190310849
Principal investigator 1 ABBVIE INC. $7,500.00 11/05/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide No dispute reported 06/30/2026 1202522379
Principal investigator 1 ABBVIE INC. $5,000.00 11/05/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide No dispute reported 06/30/2026 1202522429
Principal investigator 1 ABBVIE INC. $3,000.00 11/05/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation No dispute reported 06/30/2026 1202522493
Principal investigator 1 Seqirus USA Inc $2,564.40 11/03/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250809737
Principal investigator 1 Seqirus USA Inc $704.70 11/03/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250809742
Principal investigator 1 ModernaTX, Inc. $5,760.80 10/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252955391
Principal investigator 1 ModernaTX, Inc. $37,240.00 10/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252955519
Principal investigator 1 ModernaTX, Inc. $44,292.80 10/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252955521
Principal investigator 1 SANOFI PASTEUR INC. $5,075.00 10/23/2025 Non-covered Recipient Entity
Velocity Clinical Research
A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers No dispute reported 06/30/2026 1226114890
Principal investigator 1 Currax Pharmaceuticals LLC $5,469.80 10/14/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242718128
Principal investigator 1 GlaxoSmithKline, LLC. $197.12 10/14/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, DOSE FINDING STUDY TO No dispute reported 06/30/2026 1192130932
Principal investigator 1 SANOFI US SERVICES INC. $4,800.00 10/14/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226130700
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $493.29 10/14/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046674
Principal investigator 1 Novavax Inc $1,323.55 10/09/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age No dispute reported 06/30/2026 1242921252
Principal investigator 1 ModernaTX, Inc. $6,236.81 10/03/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252955393
Principal investigator 1 ModernaTX, Inc. $1,000.00 10/03/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252955465
Principal investigator 1 ModernaTX, Inc. $3,000.00 10/03/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252955505
Principal investigator 1 SANOFI US SERVICES INC. $76,859.00 09/29/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226130696
Principal investigator 1 Novavax Inc $4,522.44 09/25/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age No dispute reported 06/30/2026 1242920850
Principal investigator 1 AstraZeneca Pharmaceuticals LP $18,500.00 09/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A Phase III Randomised Double Blind PlaceboControlled Parallel Group Study to Assess the Effect of AZD0780 on Low Density Lipoprotein Cholesterol in Patients With Elevated Low Density Lipoprotein Cholesterol and Clinical Atherosclerotic Cardiovascular Disease or at Risk for a First Atherosclerotic Cardiovascular Disease Event No dispute reported 06/30/2026 1185550703
Principal investigator 1 SANOFI US SERVICES INC. $1,634.50 09/22/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of Itepekimab in Adult Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps No dispute reported 06/30/2026 1226130693
Principal investigator 1 BioMarin Pharmaceutical Inc. $21,500.00 09/19/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc.
BMN 111-210 No dispute reported 06/30/2026 1248580692
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $7,641.20 09/18/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046676
Principal investigator 1 GlaxoSmithKline, LLC. $2,650.00 09/04/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, DOSE FINDING STUDY TO No dispute reported 06/30/2026 1192133297
Principal investigator 1 AstraZeneca Pharmaceuticals LP $52,630.60 09/03/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
a phase one,open label,single dose study to evaluate the pharmacokinetics of inhaled in adolescents with asthma No dispute reported 06/30/2026 1185550713
Principal investigator 1 Seqirus USA Inc $111.30 09/03/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185276820
Principal investigator 1 Seqirus USA Inc $177.19 09/03/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185276840
Principal investigator 1 Seqirus USA Inc $789.00 09/03/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185276850
Principal investigator 1 Novavax Inc $761.82 08/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age No dispute reported 06/30/2026 1242918777
Principal investigator 1 Genentech, Inc. $13,962.00 08/26/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A phase IIIB surveillance study of susceptibility to baloxavir marboxil No dispute reported 06/30/2026 1211682096
Principal investigator 1 Kedrion Biopharma, Inc. $2,000.00 08/25/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
KEDBEN60-0D1OMG No dispute reported 06/30/2026 1208554919
Principal investigator 1 Kedrion Biopharma, Inc. $4,850.00 08/25/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
KEDBEN60-0D1OMG No dispute reported 06/30/2026 1208554921
Principal investigator 1 Kedrion Biopharma, Inc. $12,000.00 08/25/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
KEDBEN60-0D1OMG No dispute reported 06/30/2026 1208554923
Principal investigator 1 Kedrion Biopharma, Inc. $750.00 08/25/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
KEDBEN60-0D1OMG No dispute reported 06/30/2026 1208554925
Principal investigator 1 Kedrion Biopharma, Inc. $1,000.00 08/25/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
KEDBEN60-0D1OMG No dispute reported 06/30/2026 1208554927
Principal investigator 1 Kedrion Biopharma, Inc. $850.00 08/25/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
KEDBEN60-0D1OMG No dispute reported 06/30/2026 1208554929
Principal investigator 1 Kedrion Biopharma, Inc. $1,000.00 08/25/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
KEDBEN60-0D1OMG No dispute reported 06/30/2026 1208554931
Principal investigator 1 SANOFI US SERVICES INC. $1,172.00 08/18/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226130597
Principal investigator 1 SANOFI US SERVICES INC. $2,388.70 08/18/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226130607
Principal investigator 1 SANOFI US SERVICES INC. $175.00 08/11/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226130599
Principal investigator 1 SANOFI US SERVICES INC. $5,211.50 08/11/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226130622
Principal investigator 1 Novavax Inc $6,402.35 08/06/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age No dispute reported 06/30/2026 1242919116
Principal investigator 1 Seqirus USA Inc $2,000.00 07/30/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185277155
Principal investigator 1 Seqirus USA Inc $14,500.00 07/30/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185277157
Principal investigator 1 Seqirus USA Inc $27,126.40 07/30/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185277159
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 07/29/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046694
Principal investigator 1 ModernaTX, Inc. $1,180.59 07/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252955413
Principal investigator 1 ModernaTX, Inc. $985.50 07/25/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252955487
Principal investigator 1 ModernaTX, Inc. $985.50 07/25/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252955489
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $700.00 07/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046678
Principal investigator 1 GlaxoSmithKline, LLC. $1,150.00 07/21/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192133334
Principal investigator 1 ModernaTX, Inc. $11,840.00 07/21/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003513
Principal investigator 1 SANOFI US SERVICES INC. $14,300.00 07/14/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226130501
Principal investigator 1 SANOFI US SERVICES INC. $3,296.80 07/14/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226130541
Principal investigator 1 ABBVIE INC. $3,613.00 07/02/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide No dispute reported 06/30/2026 1202494659
Principal investigator 1 SANOFI US SERVICES INC. $1,122.00 07/02/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of Itepekimab in Adult Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps No dispute reported 06/30/2026 1226130519
Principal investigator 1 SANOFI US SERVICES INC. $325.00 07/02/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226130526
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,725.00 06/26/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older No dispute reported 06/30/2026 1185550715
Principal investigator 1 Currax Pharmaceuticals LLC $5,221.17 06/24/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717942
Principal investigator 1 Currax Pharmaceuticals LLC $515.13 06/24/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242718020
Principal investigator 1 ModernaTX, Inc. $787.06 06/18/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252955417
Principal investigator 1 SANOFI US SERVICES INC. $4,310.00 06/16/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226130409
Principal investigator 1 SANOFI US SERVICES INC. $2,500.00 06/16/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226130431
Principal investigator 1 SANOFI US SERVICES INC. $4,856.70 06/16/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226130435
Principal investigator 1 SANOFI US SERVICES INC. $750.00 06/16/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226130440
Principal investigator 1 SANOFI US SERVICES INC. $3,850.00 06/16/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226130443
Principal investigator 1 Novavax Inc $4,570.92 06/13/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age No dispute reported 06/30/2026 1242919985
Principal investigator 1 ModernaTX, Inc. $114,000.00 06/12/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003517
Principal investigator 1 ABBVIE INC. $1,500.00 06/11/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide No dispute reported 06/30/2026 1202490869
Principal investigator 1 Genentech, Inc. $1,023.00 06/11/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A phase IIIB surveillance study of susceptibility to baloxavir marboxil No dispute reported 06/30/2026 1211682086
Principal investigator 1 ModernaTX, Inc. $15,298.25 06/06/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252955529
Principal investigator 1 ABBVIE INC. $7,500.00 06/05/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation No dispute reported 06/30/2026 1202490449
Principal investigator 1 Currax Pharmaceuticals LLC $247.00 06/05/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717617
Principal investigator 1 Currax Pharmaceuticals LLC $617.50 06/05/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717799
Principal investigator 1 GlaxoSmithKline, LLC. $5,000.00 06/05/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, DOSE FINDING STUDY TO No dispute reported 06/30/2026 1192130939
Principal investigator 1 ModernaTX, Inc. $495.00 06/05/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003509
Principal investigator 1 ModernaTX, Inc. $22,925.00 06/05/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003511
Principal investigator 1 Novavax Inc $5,015.25 06/05/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age No dispute reported 06/30/2026 1242920857
Principal investigator 1 ModernaTX, Inc. $4,050.00 06/04/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252955457
Principal investigator 1 ModernaTX, Inc. $135.00 06/04/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252955459
Principal investigator 1 ModernaTX, Inc. $100.00 06/04/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252955545
Principal investigator 1 ModernaTX, Inc. $561.00 06/02/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1252955423
Principal investigator 1 ModernaTX, Inc. $500.00 06/02/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1252955471
Principal investigator 1 Currax Pharmaceuticals LLC $9,288.51 05/28/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717867
Principal investigator 1 ModernaTX, Inc. $744.80 05/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252955429
Principal investigator 1 ModernaTX, Inc. $2,802.00 05/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252955431
Principal investigator 1 ModernaTX, Inc. $53,716.80 05/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252955433
Principal investigator 1 ModernaTX, Inc. $149,780.80 05/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252955485
Principal investigator 1 ModernaTX, Inc. $1,574.12 05/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252955549
Principal investigator 1 SANOFI US SERVICES INC. $198.58 05/27/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of Itepekimab in Adult Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps No dispute reported 06/30/2026 1226130383
Principal investigator 1 Merck Sharp & Dohme LLC $104,611.00 05/26/2025 Non-covered Recipient Entity
Velocity Clinical Research, Lafayette
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Children and Adolescents With Increased Risk of Pneumococcal Disease No dispute reported 06/30/2026 1232934324
Principal investigator 1 ModernaTX, Inc. $98,800.00 05/22/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003515
Principal investigator 1 ModernaTX, Inc. $334.00 05/22/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003523
Principal investigator 1 ModernaTX, Inc. $3,602.62 05/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive No dispute reported 06/30/2026 1252955409
Principal investigator 1 ModernaTX, Inc. $1,000.00 05/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive No dispute reported 06/30/2026 1252955451
Principal investigator 1 ModernaTX, Inc. $1,550.00 05/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive No dispute reported 06/30/2026 1252955453
Principal investigator 1 ModernaTX, Inc. $780.00 05/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive No dispute reported 06/30/2026 1252955495
Principal investigator 1 Novavax Inc $15,867.29 05/15/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age No dispute reported 06/30/2026 1242919982
Principal investigator 1 GlaxoSmithKline, LLC. $749.32 05/14/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192133316
Principal investigator 1 ModernaTX, Inc. $13,399.50 05/14/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age No dispute reported 06/30/2026 1252955449
Principal investigator 1 ABBVIE INC. $1,000.00 05/08/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide No dispute reported 06/30/2026 1202484361
Principal investigator 1 ABBVIE INC. $750.00 05/08/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation No dispute reported 06/30/2026 1202484363
Principal investigator 1 ABBVIE INC. $1,000.00 05/08/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation No dispute reported 06/30/2026 1202484365
Principal investigator 1 ABBVIE INC. $1,000.00 05/08/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation No dispute reported 06/30/2026 1202484367
Principal investigator 1 SANOFI US SERVICES INC. $2,537.00 05/05/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226130363
Principal investigator 1 AstraZeneca Pharmaceuticals LP $12,969.00 05/02/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma No dispute reported 06/30/2026 1185550709
Principal investigator 1 ModernaTX, Inc. $2,809.61 05/01/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants No dispute reported 06/30/2026 1252955533
Principal investigator 1 ModernaTX, Inc. $3,040.00 04/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003497
Principal investigator 1 ModernaTX, Inc. $1,670.00 04/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003519
Principal investigator 1 Currax Pharmaceuticals LLC $6,872.82 04/24/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717747
Principal investigator 1 Novavax Inc $14,020.55 04/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age No dispute reported 06/30/2026 1242919105
Principal investigator 1 Novavax Inc $19,944.45 04/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age No dispute reported 06/30/2026 1242919978
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $7,200.00 04/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
An Open Label, Single Dose, 3-Period, Crossover Study to Determine the Pharmacokinetic Profile and Safety of Fluticasone Propionate/Albuterol Sulfate (Fp/ABS) Multidose Dry Powder Inhaler with e-Module (eMDPI) Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Participants with Asthma (4 to 11 Years Old) No dispute reported 06/30/2026 1244046684
Principal investigator 1 ModernaTX, Inc. $14,934.87 04/23/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252955525
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,400.00 04/17/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046680
Principal investigator 1 ModernaTX, Inc. $5,000.00 04/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252955385
Principal investigator 1 ModernaTX, Inc. $11,600.00 04/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252955483
Principal investigator 1 ModernaTX, Inc. $9,000.00 04/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252955523
Principal investigator 1 ModernaTX, Inc. $2,057.17 04/11/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants No dispute reported 06/30/2026 1252955493
Principal investigator 1 ModernaTX, Inc. $500.86 04/11/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants No dispute reported 06/30/2026 1252955531
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,960.00 04/10/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
An Open Label, Single Dose, 3-Period, Crossover Study to Determine the Pharmacokinetic Profile and Safety of Fluticasone Propionate/Albuterol Sulfate (Fp/ABS) Multidose Dry Powder Inhaler with e-Module (eMDPI) Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Participants with Asthma (4 to 11 Years Old) No dispute reported 06/30/2026 1244046686
Principal investigator 1 ModernaTX, Inc. $1,869.00 04/09/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age No dispute reported 06/30/2026 1252955405
Principal investigator 1 ABBVIE INC. $750.00 04/04/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide No dispute reported 06/30/2026 1202474374
Principal investigator 1 Genentech, Inc. $10,080.00 04/02/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A phase IIIB surveillance study of susceptibility to baloxavir marboxil No dispute reported 06/30/2026 1211682094
Principal investigator 1 SANOFI US SERVICES INC. $8,178.10 04/02/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226130267
Principal investigator 1 SANOFI US SERVICES INC. $1,525.50 04/02/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226130303
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,660.00 03/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler No dispute reported 06/30/2026 1185550705
Principal investigator 1 GlaxoSmithKline, LLC. $5,000.00 03/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, DOSE FINDING STUDY TO No dispute reported 06/30/2026 1192130920
Principal investigator 1 Novavax Inc $14,022.10 03/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age No dispute reported 06/30/2026 1242919120
Principal investigator 1 Eli Lilly and Company $43,608.29 03/26/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
EFFICACY, SAFETY, AND PHARMACOKINETICS OF ORFORGLIPRON ONCE DAILY ORAL VERSUS PLACEBO IN ADOLESCENT PARTICIPANTS WHO HAVE OBESITY, OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES - A RANDOMIZED, DOUBLE-BLIND TRIAL (ADVANCE-ATTAIN-ADOLESCENTS) No dispute reported 06/30/2026 1187892652
Principal investigator 1 ModernaTX, Inc. $777.09 03/26/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants No dispute reported 06/30/2026 1252955399
Principal investigator 1 ModernaTX, Inc. $625.00 03/26/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants No dispute reported 06/30/2026 1252955491
Principal investigator 1 ModernaTX, Inc. $1,300.00 03/26/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants No dispute reported 06/30/2026 1252955535
Principal investigator 1 ModernaTX, Inc. $13,281.00 03/26/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age No dispute reported 06/30/2026 1252955539
Principal investigator 1 ModernaTX, Inc. $5,994.00 03/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252955497
Principal investigator 1 ModernaTX, Inc. $1,520.00 03/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003495
Principal investigator 1 ModernaTX, Inc. $1,336.00 03/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003505
Principal investigator 1 GlaxoSmithKline, LLC. $1,750.00 03/19/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192133311
Principal investigator 1 GlaxoSmithKline, LLC. $2,500.00 03/19/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192133328
Principal investigator 1 SANOFI US SERVICES INC. $25,688.10 03/17/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226130263
Principal investigator 1 GlaxoSmithKline, LLC. $2,750.00 03/14/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, DOSE FINDING STUDY TO No dispute reported 06/30/2026 1192130903
Principal investigator 1 GlaxoSmithKline, LLC. $5,000.00 03/14/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, DOSE FINDING STUDY TO No dispute reported 06/30/2026 1192130913
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 03/14/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, DOSE FINDING STUDY TO No dispute reported 06/30/2026 1192130926
Principal investigator 1 SANOFI PASTEUR INC. $13,267.00 03/14/2025 Non-covered Recipient Entity
Velocity Clinical Research,inc
A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers No dispute reported 06/30/2026 1226091274
Principal investigator 1 SANOFI PASTEUR INC. $650.00 03/14/2025 Non-covered Recipient Entity
Velocity Clinical Research,inc
A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers No dispute reported 06/30/2026 1226091290
Principal investigator 1 ModernaTX, Inc. $4,590.00 03/12/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age No dispute reported 06/30/2026 1252955447
Principal investigator 1 ModernaTX, Inc. $1,300.00 03/12/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age No dispute reported 06/30/2026 1252955537
Principal investigator 1 ModernaTX, Inc. $330.75 03/10/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252955411
Principal investigator 1 ModernaTX, Inc. $303.75 03/10/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252955461
Principal investigator 1 ModernaTX, Inc. $429.30 03/10/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252955501
Principal investigator 1 ModernaTX, Inc. $810.00 03/10/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252955503
Principal investigator 1 ModernaTX, Inc. $945.00 03/10/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252955543
Principal investigator 1 Currax Pharmaceuticals LLC $1,683.50 03/06/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717199
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $13,426.00 03/06/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
An Open Label, Single Dose, 3-Period, Crossover Study to Determine the Pharmacokinetic Profile and Safety of Fluticasone Propionate/Albuterol Sulfate (Fp/ABS) Multidose Dry Powder Inhaler with e-Module (eMDPI) Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Participants with Asthma (4 to 11 Years Old) No dispute reported 06/30/2026 1244046688
Principal investigator 1 Currax Pharmaceuticals LLC $35,167.64 03/05/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717472
Principal investigator 1 ModernaTX, Inc. $663.00 03/05/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1252955563
Principal investigator 1 PFIZER INC. $12,759.60 03/05/2025 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1228783298
Principal investigator 1 SANOFI US SERVICES INC. $14,800.00 03/04/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of Itepekimab in Adult Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps No dispute reported 06/30/2026 1226130295
Principal investigator 1 ModernaTX, Inc. $104.00 02/28/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252955387
Principal investigator 1 Kedrion Biopharma, Inc. $300.00 02/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
KEDBEN60-0D1OMG No dispute reported 06/30/2026 1208554961
Principal investigator 1 ModernaTX, Inc. $1,525.15 02/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1252955475
Principal investigator 1 ModernaTX, Inc. $513.00 02/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1252955511
Principal investigator 1 ModernaTX, Inc. $3,006.00 02/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003493
Principal investigator 1 ModernaTX, Inc. $4,560.00 02/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003507
Principal investigator 1 ModernaTX, Inc. $5,225.00 02/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003525
Principal investigator 1 Novavax Inc $28,170.06 02/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age No dispute reported 06/30/2026 1242919111
Principal investigator 1 ModernaTX, Inc. $280.00 02/26/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252955455
Principal investigator 1 ModernaTX, Inc. $2,706.21 02/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1252955427
Principal investigator 1 SANOFI US SERVICES INC. $24,696.00 02/24/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226130207
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $204.60 02/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046692
Principal investigator 1 ModernaTX, Inc. $19,168.50 02/21/2025 Non-covered Recipient Entity
MEDPHARMICS LLC
A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive No dispute reported 06/30/2026 1252955407
Principal investigator 1 ModernaTX, Inc. $280.00 02/19/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252955463
Principal investigator 1 ModernaTX, Inc. $325.00 02/19/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252955541
Principal investigator 1 ModernaTX, Inc. $750.00 02/19/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252955547
Principal investigator 1 ModernaTX, Inc. $83.20 02/18/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252955389
Principal investigator 1 ModernaTX, Inc. $472.50 02/10/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1252955421
Principal investigator 1 ModernaTX, Inc. $93.96 02/10/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1252955425
Principal investigator 1 ModernaTX, Inc. $182.25 02/10/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1252955467
Principal investigator 1 ModernaTX, Inc. $122.85 02/10/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1252955469
Principal investigator 1 ModernaTX, Inc. $148.50 02/10/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1252955473
Principal investigator 1 ModernaTX, Inc. $137.70 02/10/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1252955477
Principal investigator 1 ModernaTX, Inc. $13.50 02/10/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1252955479
Principal investigator 1 ModernaTX, Inc. $202.50 02/10/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1252955507
Principal investigator 1 ModernaTX, Inc. $270.00 02/10/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1252955509
Principal investigator 1 ModernaTX, Inc. $384.75 02/10/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1252955515
Principal investigator 1 ModernaTX, Inc. $749.25 02/10/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1252955551
Principal investigator 1 ModernaTX, Inc. $114.75 02/10/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1252955553
Principal investigator 1 ModernaTX, Inc. $43.20 02/10/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1252955557
Principal investigator 1 ModernaTX, Inc. $336.15 02/10/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1252955561
Principal investigator 1 ModernaTX, Inc. $469.80 02/10/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1252955565
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 02/06/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, DOSE FINDING STUDY TO No dispute reported 06/30/2026 1192130945
Principal investigator 1 ModernaTX, Inc. $350.00 02/05/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252955415
Principal investigator 1 ModernaTX, Inc. $325.00 02/05/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252955499
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $409.20 02/05/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046690
Principal investigator 1 Currax Pharmaceuticals LLC $1,100.00 01/30/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717299
Principal investigator 1 Currax Pharmaceuticals LLC $2,843.78 01/30/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717315
Principal investigator 1 AstraZeneca Pharmaceuticals LP $65,366.95 01/29/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1185550707
Principal investigator 1 AstraZeneca Pharmaceuticals LP $20,274.00 01/29/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
Levante A Phase 2b Randomised Double Blind Placebo Controlled Dose Range Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630 No dispute reported 06/30/2026 1185550717
Principal investigator 1 ModernaTX, Inc. $2,750.00 01/29/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants No dispute reported 06/30/2026 1252955395
Principal investigator 1 ModernaTX, Inc. $105.00 01/29/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants No dispute reported 06/30/2026 1252955397
Principal investigator 1 ModernaTX, Inc. $1,000.00 01/29/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants No dispute reported 06/30/2026 1252955401
Principal investigator 1 ModernaTX, Inc. $850.00 01/29/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants No dispute reported 06/30/2026 1252955441
Principal investigator 1 ModernaTX, Inc. $400.00 01/29/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants No dispute reported 06/30/2026 1252955443
Principal investigator 1 ModernaTX, Inc. $1,200.00 01/29/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants No dispute reported 06/30/2026 1252955445
Principal investigator 1 ModernaTX, Inc. $3,040.00 01/29/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003499
Principal investigator 1 ModernaTX, Inc. $12,540.00 01/29/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003501
Principal investigator 1 ModernaTX, Inc. $5,678.00 01/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003521
Principal investigator 1 ModernaTX, Inc. $700.00 01/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252955435
Principal investigator 1 Novavax Inc $98,774.52 01/23/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age No dispute reported 06/30/2026 1242921645
Principal investigator 1 AstraZeneca UK Limited $7,620.00 01/22/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
a randomized,double blind,multicenter,parallel group,phase IIIb 52 week study evaluating the efficacy and safety of PT027 compared with PT007 administered as needed in participants 12 to under 18 years of age with asthma ACADIA No dispute reported 06/30/2026 1185550711
Principal investigator 1 GlaxoSmithKline, LLC. $46,177.60 01/22/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 1192133303
Principal investigator 1 ModernaTX, Inc. $39,621.65 01/22/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age No dispute reported 06/30/2026 1252955403
Principal investigator 1 SANOFI US SERVICES INC. $1,556.75 01/21/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226130175
Principal investigator 1 ModernaTX, Inc. $5,000.00 01/03/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252955439
Principal investigator 1 ModernaTX, Inc. $11,190.00 01/03/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252955527
Principal investigator 1 AstraZeneca UK Limited $16,122.75 01/02/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
Multicentre,Randomised,Double blind,Parallel Group,Placebo controlled,Time to first Asthma Exacerbation Phase tree Efficacy and Safety Study of Benralizumab in Paediatric Patients with Severe Eosinophilic Asthma Dominika No dispute reported 06/30/2026 1185550701